<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328080</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00035842</org_study_id>
    <nct_id>NCT01328080</nct_id>
  </id_info>
  <brief_title>Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy</brief_title>
  <official_title>Improving Acne Keloidalis Nuchae by Inducing Matrix Metalloproteinases in Vivo Using Targeted Ultraviolet-B Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skin of Color Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the effect of targeted UV-B (a component of sunlight)
      on the treatment of acne keloidalis nuchae (AKN, or razor bumps on the back of the neck).
      The investigators believe targeted UV-B is a safe and effective way to reduce the appearance
      of AKN.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Change in Total AKN Lesions From Baseline to Week 16.</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if treatment of AKN with targeted ultraviolet B radiation will improve the clinical appearance of lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Acne Keloidalis Nuchae</condition>
  <arm_group>
    <arm_group_label>Targeted UV-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Targeted UV-B</intervention_name>
    <description>Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)</description>
    <arm_group_label>Targeted UV-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or over

          -  male gender

          -  African-American or other black ethnicity

          -  current diagnosis of acne keloidalis nuchae (razor bumps on back of neck)

        Exclusion Criteria:

          -  allergy to lidocaine or numbing medicine

          -  history of increased sensitivity to sunlight, lupus, or porphyria

          -  current use of a drug that increases sensitivity to sunlight
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Dept. of Dermatology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.skinofcolorsociety.org/</url>
    <description>Skin of Color Society (sponsor)</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2011</firstreceived_date>
  <firstreceived_results_date>April 21, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ginette Okoye, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Keloid</mesh_term>
  </condition_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
